Specific and nonspecific immune resistance enhancing activity of staphage lysate.
The immunopotentiating activity of staphage lysate (SPL) was evaluated in terms of its immune protection against lethal bacterial infection and its antitumor activity. Mice were pretreated weekly with 10(8) viable, Staphylococcus aureus, strain 18Z for 3 weeks (Induction), followed by intraperitoneal SPL injections (Elicitation) at various times in relation to infectious challenge or tumor implantation. Induction without elicitation, or elicitation alone failed to provide protection against Klebsiella pneumoniae infection and resulted in only 30-40% survival against homologous infection with pathogenic S. aureus type III, whereas combined induction and elicitation produced enhanced resistance induction and elicitation regimens resulted in 50% and 80-100% survival in mice inoculated with K. pneumoniae and S. aureus, respectively. SPL had no antitumor effect in mice implanted with median survival time resulting from induction and elicitation in animals implanted which Ehrlich's ascites. This enhancement of immune resistance may possibly be related to activation of thymus-modulated lymphocytes and macrophages by SPL.
D000276:Adjuvants, Immunologic; D000818:Animals; D001430:Bacteriocins / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000276:immunology; D005260:Female; D007109:Immunity / Q000187:drug effects; D007710:Klebsiella Infections / Q000276:immunology; D007711:Klebsiella pneumoniae; D051379:Mice; D012510:Sarcoma 180 / Q000276:immunology; D013203:Staphylococcal Infections / Q000276:immunology; D015054:Zymosan / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D001430:Bacteriocins; C030591:staphage lysate; D015054:Zymosan